Overview

Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy

Status:
Active, not recruiting

Trial end date:
2027-06-30

Target enrollment:

Participant gender:

Summary

In this study the investigators assess the impact of the eHealth-supported therapy management system CANKADO on Quality of Life in patients with HR+, HER2-locally advanced or metastatic breast cancer treated with the cyclin dependent kinase 4/6 (CDK4/6) Inhibitor Palbociclib in combination with an aromatase inhibitor or fulvestrant. Furthermore this approach will be combined with biomarker screening to identify predictive markers for and to learn more about adherence, symptoms, response, and resistance.

Phase:

Phase 4

Details

Lead Sponsor:

Palleos Healthcare GmbH

Collaborators:

AGO-B
AGO-TraFo
CANKADO
Cankado Service GmbH
Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V.
Pfizer
WSG WOMEN´S HEALTHCARE STUDY GROUP

Treatments:

Anastrozole
Exemestane
Fulvestrant
Letrozole
Palbociclib